Desperate patients get early access to experimental drug ianalumab
NCT ID NCT07244289
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program provides early access to the drug ianalumab (VAY736) for patients with serious or life-threatening conditions like immune thrombocytopenia or Sjögren's syndrome who have no other treatment options. It is not a clinical trial but a managed access program where doctors can request the drug for individual patients. The goal is to offer potential benefit when standard therapies are not available or have failed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ianalumab (also called VAY736)
- What this could lead to
- If successful, this program could provide a treatment option for patients with serious conditions who have no other alternatives.
- What could go wrong
- This is not a clinical trial but a managed access program, so data on effectiveness and safety is limited. The treatment may not work for everyone and carries potential risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EVANS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental injection aims to boost platelets in chronic blood disorder
- New combo therapy aims to boost platelets in immune disorder
- Engineered immune cells take aim at stubborn blood disorder
- Cheap drug combo may tame tough anemia
- Scientists hunt for genetic roots of rare childhood blood disorder
- New study aims to unlock the secrets of Children's rare blood diseases